Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q1 2024 · 10-Q
Revenue$1.37M$1.37M−30.1% vs Q1 2023 Net Income-$955.89K-$955.89KN/M vs Q1 2023 EPS Diluted-$0.72-$0.72N/M vs Q1 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flow-$585,158N/M Margins · derivedGross margin-21.2%−30.2 pt vs Q1 2023
Operating margin-66.9%−46.6 pt vs Q1 2023
Net margin-69.8%−45.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end